$2.63
+0.29 (+12.39%)
Open$2.39
Previous Close$2.34
Day High$2.70
Day Low$2.39
52W High$47.52
52W Low$27.38
Volume—
Avg Volume132.1K
Market Cap5.87M
P/E Ratio16.99
EPS$2.30
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,460.1% upside
Current
$2.63
$2.63
Target
$41.03
$41.03
$36.60
$41.03 avg
$68.97
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.37M | 1.35M | 1.27M |
| Net Income | -80,240 | -84,207 | -82,182 |
| Profit Margin | -5.8% | -6.2% | -6.5% |
| EBITDA | -110,674 | -111,401 | -119,566 |
| Free Cash Flow | -110,675 | -113,905 | -126,135 |
| Rev Growth | +9.2% | +20.4% | +2.6% |
| Debt/Equity | 1.35 | 1.56 | 1.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |